We are pleased to announce the official launch of our brand-new TRICALS website! Our new website provides up-to-date information about TRICALS and has many new features.
What’s new?
We have reviewed all the existing information and added a range of new content to the website, such as:
- you will easily find new information about upcoming clinical trials, such as the MAGNET platform trial.
- We will now keep you updated about developments and achievements of TRICALS on our News page. So keep an eye on this webpage if you want to stay informed about the latest news or sign up for our newsletter.
- In addition, on our new fundraising page you can read more about how you can help us in our mission. We now support the option to start your own fundraising campaign or you can donate to TRICALS directly. On our fundraising page you can read more about setting up your own campaign or you can take a look at existing ones.
- We have also listed our future events for you on our Events page. Why not find out if we have anything planned near you?
So for now, take some time to explore our new website and we hope you like it as much as we do!
Our upcoming trials
Recruiting
Phase ii
DAZALS trial
Industry trial
In this study, an investigational oral drug named dazucorilant (also called CORT113176) is being studied in people living with ALS (also known as MND) to understand its safety (side effects) and to determine if dazucorilant can slow down the worsening of the disease. The effects of dazucorilant will be compared to the effects of a placebo. This study is sponsored by Corcept Therapeutics.
Recruiting
Phase ii
CARDINALS
Industry trial
The CARDINALS clinical research study is evaluating a study drug (Utreloxastat) to see if it can help slow ALS symptoms. Researchers will also test the safety and tolerability of the study drug and how the body responds to it. The study drug is a liquid that is swallowed 2 times a day.
Recruiting
Phase ii
AP101-02
Gesponsorde Trial
In this study we investigate the safety, tolerability, pharmacodynamics markers and pharmacokinetics (how a drug is absorbed and excreted) of AP-101 in patients with familial and sporadic amyotrophic lateral sclerosis (ALS). Currently, we are only looking for patients with familial ALS (caused by a SOD1 gene mutation) to participate in the study. This study is sponsored by AL-S Pharma.
Recruiting
Phase iii
ATLAS trial
Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Recruiting
Phase iii
FUSION trial
Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Active
Phase iii
PHOENIX trial
Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Active
Phase iii
ADORE trial
Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Active
Phase iii
TUDCA-ALS
Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Related news
ENCALS consensus statement on NurOwn
Background Given the interest around the use of stem cells in ALS, […]
Story behind the participant: Peter Ambühl
Many clinical trials are looking for participants. In this new interview series, […]
Apellis reports discontinuation of MERIDIAN study
Pharmaceutical company Apellis has announced the discontinuation of the open-label phase of […]
Recording of virtual meeting - Adherence and retention in ALS clinical trials
On March 22, 2023, TRICALS organised its first virtual meeting: ‘Adherence and retention […]